| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
|
| ln Vitro |
Methylnitrosoguanidine (MNNG, 0-1100 nM; 24 h) exerts toxic and mutagenic effects on three human diploid lymphoblastoid cell lines, MIT-2, WI-L2, and GM 130 [1].
|
|---|---|
| ln Vivo |
Methylnitrosoguanidine (MNNG; 200 mg/kg; po) enhances the number of rises in Wistar albinos [2].
|
| Animal Protocol |
Animal/Disease Models: Male Wistar albino rat [2]
Doses: 200 mg/kg Route of Administration: po (po (oral gavage)) at 0 Day 14 Experimental Results: The incidence of gastric cancer in Wistar albino rats was 100%. |
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Following an oral dose of (14)C-labeled N-methyl-N'-nitro-N-nitrosoguanidine, most of the radioactivity was excreted in the urine within 24 hrs and less than 3 percent in the feces. Less than 3 percent of the radioactivity remained in the body as acid-insoluble materials at 24 to 48 hrs. Metabolism / Metabolites After oral administration of MNNG about 90% is excreted in the urine, mostly as N-methyl-N'-nitro-guanidine, in the first 9 hr. There is evidence that denitrosation of MNNG is effected by enzymes occurring in the stomach, liver and kidney. ... |
| References |
|
| Additional Infomation |
N-Methyl-N'-nitro-N-nitrosoguanidine can cause cancer according to an independent committee of scientific and health experts.
N-methyl-n'-nitro-n-nitrosoguanidine appears as a yellow powder. Melting point 244 °F. Decomposes above 212 °F. A suspected carcinogen. Extremely hazardous as a mutagen. Avoid skin contact and inhalation of of vapors. Usually stored frozen (below 32 °F) in polyethylene bottles that are tightly closed and contained in a metal can. May decomposed during prolonged storage and develop sufficient pressure in a closed container to explode. Keep away from heat, sparks, and open flame. N-methyl-N'-nitro-N-nitrosoguanidine is an N-nitroguanidine compound having nitroso and methyl substituents at the N'-position It has a role as an alkylating agent. It is functionally related to a nitroguanidine. A nitrosoguanidine derivative with potent mutagenic and carcinogenic properties. Mechanism of Action In vitro and in vivo, MNNG causes methylation of nucleic acids, forming mainly 7-methylguanine with smaller amounts of 3-methyladenine, 1-methyladenine, 3-methylcytosine and (6)o-methylguanine. ... MNNG can modify proteins by transferring its nitroguanidine residue, eg, by converting lysine into nitrohomoarginine. Cytochrome C thus modified no longer acts as an electron acceptor. Histones from ascites tumor cells contained nitrohomoarginine after MNNG treatment. |
| Molecular Formula |
C2H5N5O3
|
|---|---|
| Molecular Weight |
147.0928
|
| Exact Mass |
147.039
|
| CAS # |
70-25-7
|
| PubChem CID |
135436526
|
| Appearance |
Light yellow to yellow solid-liquid Mixture
|
| Density |
1.8±0.1 g/cm3
|
| Boiling Point |
207.8±23.0 °C at 760 mmHg
|
| Melting Point |
118°C (dec.)
|
| Flash Point |
79.5±22.6 °C
|
| Vapour Pressure |
0.2±0.4 mmHg at 25°C
|
| Index of Refraction |
1.641
|
| LogP |
-0.79
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
10
|
| Complexity |
161
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[O-][N+](N([H])/C(=N/[H])/N(C([H])([H])[H])N=O)=O
|
| InChi Key |
VZUNGTLZRAYYDE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C2H5N5O3/c1-6(5-8)2(3)4-7(9)10/h1H3,(H2,3,4)
|
| Chemical Name |
1-methyl-3-nitro-1-nitrosoguanidine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product is not stable in solution, please use freshly prepared working solution for optimal results. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~849.82 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (14.14 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (14.14 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (14.14 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.7986 mL | 33.9928 mL | 67.9856 mL | |
| 5 mM | 1.3597 mL | 6.7986 mL | 13.5971 mL | |
| 10 mM | 0.6799 mL | 3.3993 mL | 6.7986 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
